Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) First stage previously met efficacy endpoint Second stage enrolled a further 24 patients for a total of 48; efficacy and biomarker data updates expected at medical conferences during 2019 Bergen, Norway, 08 May 2019 – BerGenBio ASA (OSE: … Read more
Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® Anti-AXL antibody, BGB149, commenced phase I safety and pharmacokinetic clinical trial. Bergen, … Read more
Bergen, Norway, 24 April 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter on Wednesday, 8 May 2019. A presentation by BerGenBio’s senior management team will take place at 10:00 am CET at: Felix Konferansesenter,Bryggetorget 3,0125 Oslo. The presentation will webcast live and the link will be available at www.bergenbio.com in … Read more
Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA Accepted for presentation at ASCO in June 2019 Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present … Read more
Bergen, Norway, 15 April 2019 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 12 April 2019 where the Company announced that the Board of Directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to … Read more
Bergen, Norway, April 09 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers, announces that Richard Godfrey, BerGenBio’s Chief Executive Officer, will present an overview of the Company at the H.C. Wainwright Global Life … Read more
First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy New cohort added under existing collaborative agreement with Merck assessing the combination in previously treated advanced NSCLC Decision to extend driven by encouraging … Read more
Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL’s role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR Selective AXL inhibitor, bemcentinib, shown to reverse AXL’s effects, thus acting synergistically with immune cells and anti-cancer therapies Data further strengthens broad development opportunities for bemcentinib both as … Read more
Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy Bemcentinib + low-dose cytarabine (LDAC) achieves efficacy endpoint, warrants further investigation Three out of 10 evaluable patients (30%) reported Complete Responses (CR/CRi) Responses occurred early, improved over time and included poor risk, previously treated patients No overlapping or … Read more
Bergen, Norway, 14 March 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces today changes made to its executive team and Board of Directors, to strengthen the organisation and prepare it for late stage clinical trials towards the second half of 2019. … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.